Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V35198 | Tibulizumab (LY 3090106) | 1849636-24-3 | Tibulizumab (LY 3090106) is a quadrivalent bispecific monoclonal antibody (mAb) targeting B cell activating factor (BAFF) and IL-17A with Kds of 60 pM and 14 pM, respectively. |
|
V54889 | Tigapotide (PCK-3145) | 848084-83-3 | Tigapotide (PCK-3145) is an antitumor peptide that reduces the development of skeletal metastases associated with prostate cancer. |
|
V35197 | Tigatuzumab (CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody) | 918127-53-4 | Tigatuzumab (CS-1008) is a human IgG1 monoclonal antibody (mAb) targeting death receptor 5 (DR5). |
|
V35195 | TJ08 | 2924274-19-9 | TJ08 is a 1,2,5-trisubstituted benzimidazole analogue that can effectively induce G1/S phase arrest and induce apoptosis in a variety of cancer cells. |
|
V35189 | TMX-2164 | 2418022-85-0 | TMX-2164 is a potent, irreversible inhibitor of B-cell lymphoma 6 (BCL6) with IC50 of 152 nM. |
|
V35186 | TNIK-IN-3 | 2754265-25-1 | TNIK-IN-3 (compound 21k) is a specific and orally bioactive TNIK inhibitor (antagonist) with IC50 of 0.026 μM. |
|
V35185 | Toddaculin | 4335-12-0 | Toddaculin is a natural coumarin that induces leukemia cell differentiation and apoptosis. |
|
V52668 | Tolcapone-d4 (Ro 40-7592-d4) | 1246816-93-2 | Tolcapone-d4 is the deuterated form of Tolcapone. |
|
V56289 | Tomentosin | 33649-15-9 | Tomentosin is an anti-inflammatory sesquiterpene lactone that can be extracted from Caspian Inula flower. |
|
V35183 | Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) | 1646321-00-7 | Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody (mAb) directed against EGFR. |
|
V35182 | Topo II/HDAC-IN-1 | 2922269-18-7 | Topo II/HDAC-IN-1 (7d) displays good dual (bifunctional) inhibitory activity against Topo II and HDAC. |
|
V35181 | Topo II/HDAC-IN-2 | 2922269-24-5 | Topo II/HDAC-IN-2 (8d) displays good dual (bifunctional) inhibitory activity against Topo II and HDAC. |
|
V54823 | Topoisomerase II inhibitor 14 | 305343-00-4 | Topoisomerase II inhibitor 14 (compound 2f) is a potent inhibitor of topoisomerase II and has anti-neoplastic activity. |
|
V34712 | Topoisomerase II inhibitor 15 | 451516-79-3 | Topoisomerase II inhibitor 15 (compound 2g) is a topoisomerase II (Topoisomerase II) inhibitor. |
|
V54996 | Toralizumab (IDEC-131; Anti-Human CD40 ligand Recombinant Antibody) | 252662-47-8 | Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) directed against CD40L (CD154), consisting of human γ1 heavy chain and human kappa light chain. |
|
V52566 | Toremifene-d6 citrate (toremifene d6 citrate (citrate)) | 1246833-71-5 | Toremifene-d6 (citrate) is the deuterated form of Toremifene citrate. |
|
V35180 | TP-030-1 | 2095514-75-1 | TP-030-1 is an inhibitor (blocker/antagonist) of RIPK1. |
|
V35179 | TP-030-2 | 2095514-84-2 | TP-030-2 is a RIPK1 inhibitor (human Ki=0.43 nM; mouse IC50=100 nM). |
|
V53570 | TP4 (Nile tilapia piscidin) | 1429184-62-2 | TP4 (Nile tilapia piscidin) is an orally bioactive piscidin-like antimicrobial peptide. |
|
V16679 | Trabectedin | 114899-77-3 | Trabectedin (ET743;Ecteinascidin-743; ET-743; trade name Yondelis) is a novel antitumor agent of marine origin with potentin vitro and in vivo antitumour activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
